Literature DB >> 16908180

Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome.

Sana Sfar1, Elham Hassen, Hamadi Saad, Faouzi Mosbah, Lotfi Chouchane.   

Abstract

OBJECTIVES: Vascular endothelial growth factor (VEGF) is a potent stimulus of angiogenesis that has an important role in many human malignancies including prostate carcinoma (PCa). We evaluated the role of the functional VEGF polymorphisms as genetic markers for PCa susceptibility and prognosis.
METHODS: The study included 101 patients with PCa and [corrected] 100 age-matched healthy men. The VEGF genotypes -1154G>A were identified by allele-specific polymerase chain reaction (AS-PCR) and the genotypes -634G>C and 936C>T were identified by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR).
RESULTS: A negative association was found between VEGF -1154AA genotype and PCa risk (OR=0.27; P=0.009). Furthermore, the presence of the VEGF -1154A allele appeared to be associated with a decreased [corrected] risk of higher tumor grade (OR=0.37; P=0.01). A significant increased risk of prostate cancer was associated with the VEGF -634 (GC+CC) combined genotype (OR=1.95; P=0.02). The VEGF -634C allele was associated with the aggressive phenotype of prostate cancer as defined by the high histological grade (OR=3.48; P=0.007). The VEGF -1154A/-634G haplotype was negatively associated with PCa risk (OR=0.48; P=0.005) and high tumor grade compared to low grade (OR=0.37; P=0.02).
CONCLUSIONS: Genetic variations in the VEGF may predict not only PCa risk but also tumor aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16908180     DOI: 10.1016/j.cyto.2006.07.003

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  37 in total

1.  Vascular endothelial growth factor gene 936 C/T polymorphism in breast cancer patients.

Authors:  Aydan Eroğlu; Ayşenur Oztürk; Ragip Cam; Nejat Akar
Journal:  Med Oncol       Date:  2007-08-01       Impact factor: 3.064

2.  Associations between vascular endothelial growth factor polymorphisms and prostate cancer risk: a meta-analysis.

Authors:  Yipeng Xu; Shaoxing Zhu
Journal:  Tumour Biol       Date:  2013-10-15

Review 3.  Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview.

Authors:  S Salvi; V Conteduca; G Gurioli; D Calistri; V Casadio; U De Giorgi
Journal:  Mol Diagn Ther       Date:  2016-02       Impact factor: 4.074

4.  Vascular endothelial growth factor gene polymorphism (-634G/C) and breast cancer risk.

Authors:  Weirong Yao; Rongzeng Yan; Lin Ma; Huiping Wan; Yanmin Yu; Xia Cheng; Yingliang Li
Journal:  Tumour Biol       Date:  2014-05-10

5.  No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population.

Authors:  Ilke H Onen; Ece Konac; Muzaffer Eroglu; Cagri Guneri; Hasan Biri; Abdullah Ekmekci
Journal:  Mol Biol Rep       Date:  2007-01-11       Impact factor: 2.316

6.  Association of vascular endothelial growth factor -634G/C and receptor for advanced glycation end products G82S gene polymorphisms with diabetic retinopathy.

Authors:  Asmaa Kamal; Khaled Abu Eleinen; Ibrahem Siam
Journal:  Int J Ophthalmol       Date:  2016-08-18       Impact factor: 1.779

7.  VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab.

Authors:  Anna Luisa Di Stefano; Marianne Labussiere; Giuseppe Lombardi; Marica Eoli; Donata Bianchessi; Francesco Pasqualetti; Patrizia Farina; Stefania Cuzzubbo; Jaime Gallego-Perez-Larraya; Blandine Boisselier; Francois Ducray; Caroline Cheneau; Arrigo Moglia; Gaetano Finocchiaro; Yannick Marie; Amithys Rahimian; Khe Hoang-Xuan; Jean Yves Delattre; Karima Mokhtari; Marc Sanson
Journal:  J Neurooncol       Date:  2014-12-07       Impact factor: 4.130

8.  Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.

Authors:  Tiva T VanCleave; Jason H Moore; Marnita L Benford; Guy N Brock; Ted Kalbfleisch; Richard N Baumgartner; James W Lillard; Rick A Kittles; La Creis R Kidd
Journal:  Prostate       Date:  2010-03-01       Impact factor: 4.104

9.  Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

Authors:  Bryan P Schneider; Molin Wang; Milan Radovich; George W Sledge; Sunil Badve; Ann Thor; David A Flockhart; Bradley Hancock; Nancy Davidson; Julie Gralow; Maura Dickler; Edith A Perez; Melody Cobleigh; Tamara Shenkier; Susan Edgerton; Kathy D Miller
Journal:  J Clin Oncol       Date:  2008-10-01       Impact factor: 44.544

10.  Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China.

Authors:  Ann W Hsing; Lori C Sakoda; Asif Rashid; Gabriella Andreotti; Jinbo Chen; Bin-Shen Wang; Ming-Chang Shen; Bingshu E Chen; Philip S Rosenberg; Mingdong Zhang; Shelley Niwa; Lisa Chu; Robert Welch; Meredith Yeager; Joseph F Fraumeni; Yu-Tang Gao; Stephen J Chanock
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.